TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody

Author: Benzinga Newsdesk | July 08, 2024 06:35am

KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies
KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors
To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined
Concurrent $5 million investment from existing TuHURA shareholder preserves TuHURA's strong balance sheet for advancing its IFx-2.0 Phase 3 accelerated approval trial and novel bi-functional ADCs

Posted In: KA KTRA